Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

416 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Influencing blood usage in Germany: what is optimal use?
Schramm W, Berger K. Schramm W, et al. Transfusion. 2007 Aug;47(2 Suppl):152S-154S; discussion 155S-156S. doi: 10.1111/j.1537-2995.2007.01374.x. Transfusion. 2007. PMID: 17651341 No abstract available.
[Health economic aspects of the use of blood and blood products].
Berger K, Frey L, Spannagl M, Schramm W. Berger K, et al. Among authors: schramm w. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2006 Jan;49(1):64-72. doi: 10.1007/s00103-005-1188-1. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2006. PMID: 16362134 German.
Blood component use and associated costs after standard dose chemotherapy--a prospective analysis of routine hospital care in lymphoproliferative disorders and NSCLC in Germany.
Paessens B, Ihbe-Heffinger A, von Schilling C, Shlaen R, Bernard R, Peschel C, Schramm W, Berger K. Paessens B, et al. Among authors: schramm w. Support Care Cancer. 2012 May;20(5):1011-21. doi: 10.1007/s00520-011-1173-1. Epub 2011 May 12. Support Care Cancer. 2012. PMID: 21562801
Economics of prophylactic treatment.
Schramm W, Berger K. Schramm W, et al. Haemophilia. 2003 May;9 Suppl 1:111-5; dicussion 116. doi: 10.1046/j.1365-2516.9.s1.14.x. Haemophilia. 2003. PMID: 12709046 Review.
[The use of coagulation factors in hemophilia treatment].
Berger K, Schramm W. Berger K, et al. Among authors: schramm w. Pharm Unserer Zeit. 2006;35(1):66-73. doi: 10.1002/pauz.200500157. Pharm Unserer Zeit. 2006. PMID: 16465868 Review. German. No abstract available.
Cost effectiveness of haemophilia treatment: a cross-national assessment.
Lippert B, Berger K, Berntorp E, Giangrande P, van den Berg M, Schramm W, Siebert U; European Haemophilia Economic Study Group. Lippert B, et al. Among authors: schramm w. Blood Coagul Fibrinolysis. 2005 Oct;16(7):477-85. doi: 10.1097/01.mbc.0000178830.39526.ff. Blood Coagul Fibrinolysis. 2005. PMID: 16175006
416 results